



ASX ANNOUNCEMENT

7 August 2020

Business Update – COVID-19 Victorian Stage 4 Restrictions

IDT Australia Limited (ASX: IDT) provides the following update in regards to the COVID-19 pandemic and the Company's current and future business operations. As a Pharmaceutical Product Manufacturer, IDT is classified by the Victorian Government as a Permitted Work Premises. IDT's site is designated Open (For On-Site Work) Under a COVID Safe Plan.

Accordingly, IDT has revised its COVID Safe Plan to include additional measures associated with the Victorian Government's Stage 4 lockdown. All staff required to work on-site or from home have now been issued with the requisite official Victorian Government Permitted Worker Permits.

Since the emergence of COVID-19, IDT has implemented a range of measures designed to protect the health and safety of our employees whilst ensuring continuity of business operations. Prior to these Stage 4 restrictions, IDT had already re-implemented site restrictions of our own over a month ago in response to the increasing number of COVID-19 cases and community spread. As the COVID-19 situation evolves IDT will continue to respond in accordance with current best practice.

The Company continues to focus on its business objectives. A business continuity plan has been put in place to maximise our ability to continue to function and to respond to the challenges presented by COVID-19. We thank our staff for their exceptional dedication and commitment over this period.

IDT's GMP pharmaceutical manufacturing facilities and laboratory remain fully operational and business operations continue with minimal disruption.

Ends..../

IDT

Authorised by the Board of Directors of IDT Australia Limited. For further information please contact:

Dr David Sparling

Chief Executive Officer - IDT Australia Limited

+61 303 9801 8888

About IDT

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.